Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Oncolytic Adenovirus Market Grown from 2024 to 2025?
The market for oncolytic adenovirus has seen significant growth over the recent years. An increase from $122.31 billion in 2024 to $132.87 billion in 2025, indicative of a compound annual growth rate (CAGR) of 8.6%, is projected. This substantial growth can be traced back to various factors such as a surge in cancer cases, higher demand for specialized cancer treatments, increased funding for research and development activities, enhancements in delivery mechanisms, and regulatory green lights.
What Growth Rate Is Anticipated for the Oncolytic Adenovirus Market in the Coming Years?
Expectations indicate that the oncolytic adenovirus market will experience robust growth in the upcoming years. Its estimated value is projected to reach $183.22 billion by 2029, with a compound annual growth rate (CAGR) of 8.4%. The factors contributing to this projected growth during the forecast period include an increase in cancer cases, advancements and approvals in regulations, enhancement in combination therapies, progress in virus engineering technology, and a rise in oncology research funding. Key trends identified for the forecast period encompass progress in viral engineering methodologies, evolution in drug delivery systems, improvements in tumor targeting accuracy, advancement in combinations of immunotherapy, and developments in diagnostics and patient monitoring.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp
Who Are the Leading Companies in the Oncolytic Adenovirus Market?
Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.
What Are the Key Drivers of the Oncolytic Adenovirus Market?
The rise in cancer cases is projected to boost the progression of the oncolytic adenovirus market. Characterized by uncontrolled cellular growth and spread to various body parts, cancer is increasingly prevalent due to a variety of factors such as an aging population, lifestyle choices, exposure to certain environmental factors, genetic vulnerabilities, and enhanced detection methods. The oncolytic adenovirus strategically targets and eliminates cancer cells, presenting a potential solution for the escalating frequency of cancer. For instance, National Cancer Institute (NCI), a US-based governmental agency, reported in May 2024 that there were approximately 20 million fresh cancer cases and 9.7 million fatalities globally, with forecasts for 2040 suggesting 29.9 million cases and 15.3 million deaths. In addition, based on the data from the Australian Bureau of Statistics, a governmental agency in Australia, in 2023, 1.8% of Australians were battling cancer, with a slightly higher occurrence in males (2.1%) than in females (1.6%), most notably among individuals aged 75 and over. Consequently, the escalating numbers of cancer cases are facilitating the growth of the oncolytic adenovirus market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp
What Are the Key Market Segments in the Oncolytic Adenovirus Industry?
The oncolytic adenovirus market covered in this report is segmented –
1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types
2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications
3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes
Subsegments:
1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based, Second-generation Adenovirus Type 5-based, Engineered Adenovirus Type 5-based
2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based, Second-generation Adenovirus Type 2-based, Engineered Adenovirus Type 2-based
3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses
What Are the Latest Trends in the Oncolytic Adenovirus Market?
Prominent firms in the oncolytic adenovirus sector are emphasizing combined therapies such as VCN-01, integrating oncolytic virotherapy and chemotherapy to optimize tumor targeting and bolster therapeutic results. VCN-01 is an oncolytic adenovirus, specifically engineered to infect and obliterate cancer cells while boosting chemotherapy’s potency. For example, Theriva Biologics, an American clinical-stage immunotherapy company, revealed in May 2024 that the U.S. Food and Drug Administration (FDA) awarded Fast Track Designation (FTD) to its prime candidate, VCN-01. This designation applies to VCN-01 when administered in tandem with gemcitabine and nab-paclitaxel to cure metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that zeroes in on and replicates within tumor cells, thus aiding in dismantling the tumor stroma, a notable hindrance to effective cancer treatment.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report
What Are the Key Regional Markets in the Oncolytic Adenovirus Industry?
North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21235
This Report Delivers Insight On:
1. How big is the oncolytic adenovirus market, and how is it changing globally?
2. Who are the major companies in the oncolytic adenovirus market, and how are they performing?
3. What are the key opportunities and risks in the oncolytic adenovirus market right now?
4. Which products or customer segments are growing the most in the oncolytic adenovirus market?
5. What factors are helping or slowing down the growth of the oncolytic adenovirus market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model